Jihane Khalife

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7344068/publications.pdf

Version: 2024-02-01

9 papers	542 citations	1163117 8 h-index	1588992 8 g-index
10 all docs	10 docs citations	10 times ranked	1281 citing authors

#	Article	IF	Citations
1	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 2021, 35, 189-200.	7.2	56
2	MiR-16 regulates crosstalk in NF-ÎºB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	5.0	33
3	Copper 64â€“labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood, 2018, 131, 741-745.	1.4	54
4	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. OncoImmunology, 2018, 7, e1486948.	4.6	41
5	Effects of Ascorbic Acid on Tax, NF-ÎºB and MMP-9 in Human T-cell Lymphotropic Virus Type 1 Positive Malignant T-Lymphocytes. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 237-244.	1.7	0
6	Targeting the RAS/MAPK pathway withmiR-181ain acute myeloid leukemia. Oncotarget, 2016, 7, 59273-59286.	1.8	50
7	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. Journal of Clinical Investigation, 2014, 124, 1512-1524.	8.2	52
8	In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline. Haematologica, 2013, 98, e92-e94.	3.5	13
9	RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. Journal of Clinical Oncology, 2012, 30, 3109-3118.	1.6	242